Long-Term access to momelotinib for myelofibrosis patients
NCT ID NCT03441113
First seen Apr 23, 2026 · Last updated Apr 29, 2026 · Updated 1 time
Summary
This study offers extended access to the drug momelotinib for people with myelofibrosis, a type of bone marrow cancer. Participants had already been taking momelotinib in earlier studies and had not seen their disease get worse. The goal is to monitor long-term safety and track overall survival and leukemia-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Scottsdale, Arizona, 53226, United States
-
GSK Investigational Site
Orange, California, 97239, United States
-
GSK Investigational Site
Stanford, California, 94305-5821, United States
-
GSK Investigational Site
Aurora, Colorado, 80045, United States
-
GSK Investigational Site
Jacksonville, Florida, 32224, United States
-
GSK Investigational Site
Tampa, Florida, 33612, United States
-
GSK Investigational Site
Atlanta, Georgia, 30322, United States
-
GSK Investigational Site
Baltimore, Maryland, 21229-5299, United States
-
GSK Investigational Site
Boston, Massachusetts, 02215, United States
-
GSK Investigational Site
Rochester, Minnesota, 55905, United States
-
GSK Investigational Site
St Louis, Missouri, 63130, United States
-
GSK Investigational Site
Hackensack, New Jersey, 07601, United States
-
GSK Investigational Site
The Bronx, New York, 10467, United States
-
GSK Investigational Site
Cleveland, Ohio, 44195, United States
-
GSK Investigational Site
South Brisbane, Queensland, 4101, Australia
-
GSK Investigational Site
Bedford Park, South Australia, 5000, Australia
-
GSK Investigational Site
Frankston, Victoria, 31 99, Australia
-
GSK Investigational Site
Melbourne, Victoria, 3004, Australia
-
GSK Investigational Site
Melbourne, Victoria, 3050, Australia
-
GSK Investigational Site
Perth, Western Australia, 6000, Australia
-
GSK Investigational Site
Linz, 4020, Austria
-
GSK Investigational Site
Vienna, 1090, Austria
-
GSK Investigational Site
Antwerp, 2030, Belgium
-
GSK Investigational Site
Bruges, 8000, Belgium
-
GSK Investigational Site
Leuven, 3000, Belgium
-
GSK Investigational Site
Liège, 4000, Belgium
-
GSK Investigational Site
Pleven, 5800, Bulgaria
-
GSK Investigational Site
Rousse, 7002, Bulgaria
-
GSK Investigational Site
Sofia, 01431, Bulgaria
-
GSK Investigational Site
Sofia, 1756, Bulgaria
-
GSK Investigational Site
Toronto, Ontario, M5G 2M9, Canada
-
GSK Investigational Site
Montreal, Quebec, H3H 2R9, Canada
-
GSK Investigational Site
Montreal, Quebec, H3T 1E2, Canada
-
GSK Investigational Site
Aalborg, 9000, Denmark
-
GSK Investigational Site
Herlev, 2100, Denmark
-
GSK Investigational Site
Le Mans, 72037, France
-
GSK Investigational Site
Lille, 13273, France
-
GSK Investigational Site
Marseille, 13273, France
-
GSK Investigational Site
Paris, 75475, France
-
GSK Investigational Site
Pessac, 33604, France
-
GSK Investigational Site
Pierre-Bénite, 69495, France
-
GSK Investigational Site
Toulouse, 31059, France
-
GSK Investigational Site
Aachen, 52074, Germany
-
GSK Investigational Site
Cologne, 50937, Germany
-
GSK Investigational Site
Dresden, 01307, Germany
-
GSK Investigational Site
Halle, 06120, Germany
-
GSK Investigational Site
Leipzig, 04103, Germany
-
GSK Investigational Site
Lübeck, 79106, Germany
-
GSK Investigational Site
Mainz, 55131, Germany
-
GSK Investigational Site
Budapest, 1083, Hungary
-
GSK Investigational Site
Budapest, 1097, Hungary
-
GSK Investigational Site
Debrecen, 4032, Hungary
-
GSK Investigational Site
Győr, 9024, Hungary
-
GSK Investigational Site
Kaposvár, 7400, Hungary
-
GSK Investigational Site
Nyíregyháza, 4400, Hungary
-
GSK Investigational Site
Tatabánya, 2800, Hungary
-
GSK Investigational Site
Afula, 18101, Israel
-
GSK Investigational Site
Ashkelon, 7830604, Israel
-
GSK Investigational Site
Haifa, 3436212, Israel
-
GSK Investigational Site
Jerusalem, 9112001, Israel
-
GSK Investigational Site
Kfar Saba, 44281, Israel
-
GSK Investigational Site
Bologna, 40138, Italy
-
GSK Investigational Site
Florence, 50134, Italy
-
GSK Investigational Site
Genova, 16132, Italy
-
GSK Investigational Site
Milan, 20122, Italy
-
GSK Investigational Site
Monza, 20900, Italy
-
GSK Investigational Site
Naples, 80131, Italy
-
GSK Investigational Site
Pesaro, 61122, Italy
-
GSK Investigational Site
Rionero in Vulture PZ, 85028, Italy
-
GSK Investigational Site
Roma, 00161, Italy
-
GSK Investigational Site
Torino, 10126, Italy
-
GSK Investigational Site
Torino, 10128, Italy
-
GSK Investigational Site
Verona, 37134, Italy
-
GSK Investigational Site
Maastricht, 6229 ER, Netherlands
-
GSK Investigational Site
Brzozów, 36-200, Poland
-
GSK Investigational Site
Chorzów, 41-500, Poland
-
GSK Investigational Site
Gdansk, 80-214, Poland
-
GSK Investigational Site
Krakow, 30-688, Poland
-
GSK Investigational Site
Lublin, 20-081, Poland
-
GSK Investigational Site
Opole, 45-061, Poland
-
GSK Investigational Site
Poznan, 60-631, Poland
-
GSK Investigational Site
Brasov, 500152, Romania
-
GSK Investigational Site
Bucharest, 022328, Romania
-
GSK Investigational Site
Bucharest, 030171, Romania
-
GSK Investigational Site
Cluj-Napoca, 400124, Romania
-
GSK Investigational Site
Craiova, 200143, Romania
-
GSK Investigational Site
Iași, 700111, Romania
-
GSK Investigational Site
Singapore, 169608, Singapore
-
GSK Investigational Site
Singapore, 188770, Singapore
-
GSK Investigational Site
Busan, 48108, South Korea
-
GSK Investigational Site
Daegu, 700-721, South Korea
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Seoul, 03722, South Korea
-
GSK Investigational Site
Seoul, 135-710, South Korea
-
GSK Investigational Site
Seoul, 137-701, South Korea
-
GSK Investigational Site
Barcelona, 08003, Spain
-
GSK Investigational Site
Barcelona, 08035, Spain
-
GSK Investigational Site
Barcelona, 08916, Spain
-
GSK Investigational Site
Madrid, 28034, Spain
-
GSK Investigational Site
Madrid, 28041, Spain
-
GSK Investigational Site
Madrid, 28222, Spain
-
GSK Investigational Site
Pamplona, 31008, Spain
-
GSK Investigational Site
Zaragoza, 50012, Spain
-
GSK Investigational Site
Kaohsiung City, 807, Taiwan
-
GSK Investigational Site
Kaohsiung City, 833, Taiwan
-
GSK Investigational Site
Taipei, 100, Taiwan
-
GSK Investigational Site
Taoyuan District, 333, Taiwan
-
GSK Investigational Site
Airdrie, ML6 0JS, United Kingdom
-
GSK Investigational Site
Bristol, BS2 8ED, United Kingdom
-
GSK Investigational Site
Cardiff, CF14 4XW, United Kingdom
-
GSK Investigational Site
London, W12 0HS, United Kingdom
-
GSK Investigational Site
Oxford, OX3 7LE, United Kingdom
Conditions
Explore the condition pages connected to this study.